医疗机构青光眼治疗药物使用结构分析
|
摘要
目的:分析医疗机构青光眼治疗药物的使用数据,探讨医疗机构青光眼治疗药物使用结构的发展趋势。方法:通过对全国690家医疗机构药品购销数据的处理,分析医疗机构青光眼治疗药物的使用现状及使用结构;选取赫芬达尔-赫希曼指数(HHI)与集中曲线这两个指标,对医疗机构青光眼治疗药物的市场集中度进行分析。结果:医疗机构青光眼治疗药物使用金额及使用量整体呈现上升趋势,其中前列腺素类药物使用金额(占比)及使用量(占比)均呈现明显的上升趋势,而非前列腺素类药物使用金额及使用量略有所上升,使用金额占比及使用量占比均呈现下降趋势;医疗机构青光眼治疗药物的产品集中度较高,并逐年上升;医疗机构青光眼治疗药物的产品集中度较高。结论:医疗机构青光眼治疗药物的使用趋于集中,前列腺素类药物在青光眼治疗药物中扮演日益重要的角色。
Objective: To analyze the data of anti-glaucoma drugs and explore the development trend of anti-glaucoma drugs in medical institutions. Methods: The purchase and sale data of 690 nationwide medical institutions was analyzed in aspect of the status and constitution of anti-glaucoma drugs. Besides,Herfindahl-Hirschman Index( HHI) and market concentration curve were used to reflect the market concentration rate of anti-glaucoma drugs in medical institutions. Results: The expense and amount of anti-glaucoma drugs in medical institutions showed a general upward trend,in which the expense( share) and amount( share) of prostaglandin drugs presented obvious upward trend,while the expense and amount of non-prostaglandin drugs increased slightly and the expense share and amount share of non-prostaglandin drugs showed a downward trend. The manufacturers of antiglaucoma drugs highly concentrated and the degree of concentraion increased year by year. Besides,the product concentration of anti-glaucoma drugs used in medical institutions was in a relatively high degree. Conclusion: Anti-glaucoma drugs used in medical institutions show a concentration tendency,and prostaglandin drugs play a more and more important role in glaucoma medications.
Objective: To analyze the data of anti-glaucoma drugs and explore the development trend of anti-glaucoma drugs in medical institutions. Methods: The purchase and sale data of 690 nationwide medical institutions was analyzed in aspect of the status and constitution of anti-glaucoma drugs. Besides,Herfindahl-Hirschman Index( HHI) and market concentration curve were used to reflect the market concentration rate of anti-glaucoma drugs in medical institutions. Results: The expense and amount of anti-glaucoma drugs in medical institutions showed a general upward trend,in which the expense( share) and amount( share) of prostaglandin drugs presented obvious upward trend,while the expense and amount of non-prostaglandin drugs increased slightly and the expense share and amount share of non-prostaglandin drugs showed a downward trend. The manufacturers of antiglaucoma drugs highly concentrated and the degree of concentraion increased year by year. Besides,the product concentration of anti-glaucoma drugs used in medical institutions was in a relatively high degree. Conclusion: Anti-glaucoma drugs used in medical institutions show a concentration tendency,and prostaglandin drugs play a more and more important role in glaucoma medications.
引文
[1]中华医学会眼科学分会[EB/OL].(2015-02-05).http://www.cmao.org.cn/news_view.asp?id=199.
[2]QUIGLEY HA,BROMAN AT.The number of people with glaucoma worldwide in 2010 and 2020[J].Br J Ophthalmol,2006,90(3):262-269.
[3]中华医学会眼科学分会[EB/OL].(2015-02-05).http://www.cmao.org.cn/news_view.asp?id=290.
[4]孔彦月,张莉.青光眼药物治疗及合理应用[J].中国现代药物应用,2012,6(18):123-125.
[5]FECHTNER RD,MCCARROLL KA,LINES CR,et al.Efficacy of the dorzolamide/timolol fixed combination versus latanoprost in the treatment of ocular hypertension or glaucoma:combined analysis of pooled data from two large randomized observer and patient-masked studies[J].J Ocular Pharmacol Ther,2005,21(3):242-249.
[6]RINTARO SUZUKI JR E,MEIRELLES FRANKLIN L,BASILIO DA SILVA LJ,et al.Comparison of the efficacy and safety of travoprost with a fixed-combination of dorzolamide and timolol in patients with open-angle glaucoma or ocular hypertension[J].Curr Med Res Opin,2006,22(9):1799-1805.
[7]武峰,赵秀丽.治疗青光眼药物的研究进展[J].中华眼科医学杂志(电子版),2011,1(1):74-80.
[8]任泽钦.青光眼局部降眼压药专家共识和一线药物的发展[J].眼科,2012,21(1):11-13.
[9]郭恺.市场规模与市场集中的关系研究[D].济南:山东大学,2006.
[10]于小婷,韩晟,张慕禹,等.我国医疗机构抗肿瘤药物行业集中度分析[J].中国新药杂志,2013,22(24):2852-2855.
[11]封肖云.FDI与中国市场集中度的相关性分析[D].济南:山东大学,2006.
[12]王炳文.中国煤炭产业集中度及政策研究[D].北京:北京交通大学,2013.
[2]QUIGLEY HA,BROMAN AT.The number of people with glaucoma worldwide in 2010 and 2020[J].Br J Ophthalmol,2006,90(3):262-269.
[3]中华医学会眼科学分会[EB/OL].(2015-02-05).http://www.cmao.org.cn/news_view.asp?id=290.
[4]孔彦月,张莉.青光眼药物治疗及合理应用[J].中国现代药物应用,2012,6(18):123-125.
[5]FECHTNER RD,MCCARROLL KA,LINES CR,et al.Efficacy of the dorzolamide/timolol fixed combination versus latanoprost in the treatment of ocular hypertension or glaucoma:combined analysis of pooled data from two large randomized observer and patient-masked studies[J].J Ocular Pharmacol Ther,2005,21(3):242-249.
[6]RINTARO SUZUKI JR E,MEIRELLES FRANKLIN L,BASILIO DA SILVA LJ,et al.Comparison of the efficacy and safety of travoprost with a fixed-combination of dorzolamide and timolol in patients with open-angle glaucoma or ocular hypertension[J].Curr Med Res Opin,2006,22(9):1799-1805.
[7]武峰,赵秀丽.治疗青光眼药物的研究进展[J].中华眼科医学杂志(电子版),2011,1(1):74-80.
[8]任泽钦.青光眼局部降眼压药专家共识和一线药物的发展[J].眼科,2012,21(1):11-13.
[9]郭恺.市场规模与市场集中的关系研究[D].济南:山东大学,2006.
[10]于小婷,韩晟,张慕禹,等.我国医疗机构抗肿瘤药物行业集中度分析[J].中国新药杂志,2013,22(24):2852-2855.
[11]封肖云.FDI与中国市场集中度的相关性分析[D].济南:山东大学,2006.
[12]王炳文.中国煤炭产业集中度及政策研究[D].北京:北京交通大学,2013.